目录 CONTENTS 公司简介 | 公司加入的协会 | 03 | | --- | --- | | 公司 2024 年获得荣誉 | 04 | | 环境、社会及公司治理 | 07 | 稳健经营 11 | 公司治理 | 13 | | --- | --- | | 党建引领 | 17 | | 商业道德 | 18 | | 供应商管理 | 18 | | 创新管理 | 23 | | --- | --- | | 产品质量和食品安全 | 32 | | 客户关系管理 | 35 | 49 环境保护 | 环境管理体系 | 51 | | --- | --- | | 应对气候变化 | 51 | | 污染防治 | 55 | | 资源循环 | 58 | 附录 | 《GRI 可持续发展报告标 | 65 | | --- | --- | | 准》内容索引 | | | 《深圳证券交易所上市 | 67 | | 公司自律监管指引 第 17 | | | 号——可持续发展报告》 | | | 对标索引 | | | 报告编制说明 | 72 | | 协作共赢 | | | --- | --- | | 人才吸引与留任 | 39 | | 人才发展 | 43 | | 健 ...

北京科拓恒通生物技术股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于2025年4月23 日在中国证监会指定信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露《北 京科拓恒通生物技术股份有限公司2024年年度报告》。 为进一步提高公司治理水平，便于广大投资者更全面、深入地了解公司情况， 公司定于2025年5月8日（星期四）下午15:00—17:00在深圳证券交易所"互动易" 平台"云访谈"栏目举行2024年度业绩说明会（以下简称"本次说明会"），现将 有关事项公告如下： 本次说明会将采用网络远程的方式举行，投资者可登陆深圳证券交易所"互 动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次会议。 证券代码：300858 证券简称：科拓生物 公告编号：2025-021 为充分尊重投资者、提升交流的针对性，现就公司本次说明会提前向投资者 公开征集问题。投资者可提前登录"互动易"平台（http://ir ...

北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开了第三届董事会第十三次会议，公司董事会决定于 2025 年 5 月 21 日以现 场投票与网络投票相结合的方式召开公司 2024 年年度股东大会（以下简称"会 议"或"本次股东大会"），现将会议的有关情况通知如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：本次股东大会的召集、召开符合有关法律、 行政法规、部门规章、其他规范性文件及《公司章程》的有关规定。 证券代码：300858 证券简称：科拓生物 公告编号：2025-020 北京科拓恒通生物技术股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 4、会议召开的日期与时间 （1）现场会议召开时间：2025年5月21日（星期三）14:30 （2）网络投票时间：2025年5月21日。其中，通过深圳证券交易所交易系统 进行网络投票的具体时间为：2025年5月21日，9:15-9:25 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-009 北京科拓恒通生物技术股份有限公司 第三届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京科拓恒通生物技术股份有限公司（以下简称"公司"）第三届监事会第 十二次会议通知于 2025 年 4 月 11 日以邮件通知方式向各位监事发出，会议于 2025 年 4 月 21 日以通讯表决方式进行。本次会议由监事会主席陈杰先生召集并 主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席了本次会 议。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简 称"公司法"）等法律法规和《北京科拓恒通生物技术股份有限公司章程》（以下 简称"公司章程"）的有关规定，会议合法、有效。 二、监事会会议审议情况 经全体与会监事认真审议，形成决议如下： （一） 审议通过《关于 2024 年度监事会工作报告的议案》 2024 年度，公司监事会严格按照《公司法》《中华人民共和国证券法》等法 律法规和《公司章程》等规章制度的要求，切实维护公 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-008 北京科拓恒通生物技术股份有限公司 第三届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、北京科拓恒通生物技术股份有限公司（以下简称"公司"）第三届董事会 第十三次会议通知于 2025 年 4 月 11 日以邮件通知方式向各位董事发出，同时列 明了会议的召开时间、内容和方式。 2、本次会议于 2025 年 4 月 21 日上午 10:00 以通讯表决方式进行。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长孙天松女士召集和主持，公司监事和高级管理人员 列席了本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下 简称"公司法"）等法律法规和《北京科拓恒通生物技术股份有限公司章程》（以 下简称"公司章程"）的有关规定，会议合法、有效。 公司独立董事刘惠玉女士、鲁绯女士、方芳女士向董事会递交了《2024 年 度独立董事述职报告》，并将在公司 2024 年年度股东大会上进行述职。 具 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-013 北京科拓恒通生物技术股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条 相关规定的可能被实施其他风险警示情形。 一、审议程序 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开第三届董事会第十三次会议、第三届监事会第十二次会议，审议通过 了《关于 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年度股 东大会审议。 （一）董事会审议情况 公司第三届董事会第十三次会议，审议通过《关于 2024 年度利润分配预案 的议案》，公司 2024 年度利润分配预案综合考虑了盈利能力、财务状况、未来发 展前景等因素，与公司经营业绩及未来发展相匹配，有利于与全体股东共享公司 的经营成果，符合《公司法》《公司章程》中关于利润分配的相关规定。 （二）监事会审议情况 景等因素，保障了股东的合理回报，不存在损害股东利益的 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-016 北京科拓恒通生物技术股份有限公司 关于作废部分已授予尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开的第三届董事会第十三次会议、第三届监事会第十二次会议，审议通 过《关于作废部分已授予尚未归属的限制性股票的议案》。现将相关内容公告如 下： 一、2024 年限制性股票激励计划已履行的相关审批程序 1、2024 年 2 月 2 日，公司召开第三届董事会第五次会议，审议通过《关于 <北京科拓恒通生物技术股份有限公司 2024 年限制性股票激励计划（草案）>及 其摘要的议案》《关于<北京科拓恒通生物技术股份有限公司 2024 年限制性股票 激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办理 2024 年限制性股票激励计划相关事宜的议案》，关联董事已回避表决。 2、2024 年 2 月 2 日，公司召开第三届监事会第五次会议，审议通过《关于 <北京科拓恒通生物技术股份 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥77,612,862.67, representing a 31.49% increase compared to ¥59,025,584.73 in the same period last year[5] - Net profit attributable to shareholders was ¥20,329,624.63, up 9.79% from ¥18,516,444.83 year-on-year[5] - Basic earnings per share increased by 14.29% to ¥0.08 from ¥0.07 in the same period last year[5] - Total operating revenue for the current period reached ¥77,612,862.67, a significant increase of 31.5% compared to ¥59,025,584.73 in the previous period[27] - Net profit for the current period was ¥20,329,624.63, representing an increase of 9.8% from ¥18,516,444.83 in the previous period[28] Cash Flow - The net cash flow from operating activities was negative at -¥529,716.47, a decline of 101.84% compared to ¥28,714,195.39 in the previous year[14] - The company's cash flow from operating activities showed improvement, with a notable increase in cash inflows compared to the previous period[29] - Operating cash inflow totaled $66,962,274.75, down 24.0% from $88,076,558.40 in the previous period[30] - Operating cash outflow increased to $67,491,991.22, up 13.5% from $59,362,363.01 in the previous period[30] - Net cash flow from operating activities was negative at -$529,716.47, compared to a positive $28,714,195.39 in the previous period[30] - Cash inflow from investment activities was $456,343,362.38, a decrease of 25.3% from $611,003,135.92 in the previous period[31] - Net cash flow from investment activities increased to $102,761,836.24, up 71.5% from $59,957,195.27 in the previous period[31] - Cash outflow for purchasing fixed assets and intangible assets was $95,438,950.78, up 76.6% from $54,078,280.88 in the previous period[31] - Cash outflow from financing activities was $416,094.00, a significant decrease from $3,470,324.71 in the previous period[31] - The net increase in cash and cash equivalents was $101,816,024.92, compared to $85,201,065.95 in the previous period[32] - The ending balance of cash and cash equivalents was $207,401,392.39, down from $273,737,504.09 in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,932,060,722.81, a 0.86% increase from ¥1,915,597,694.39 at the end of the previous year[5] - Non-current assets totaled ¥858,551,717.68, down from ¥960,892,687.72 in the previous period, indicating a decrease of 10.6%[25] - Current liabilities decreased slightly to ¥94,114,470.60 from ¥96,188,516.35, a reduction of 2.2%[25] - The total current assets increased to ¥1,073,509,005.13 from ¥954,705,006.67, representing a growth of approximately 12.4%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,685[16] - The largest shareholder, Sun Tiansong, holds 19.94% of shares, totaling 52,538,822 shares[16] - The top ten shareholders hold a combined total of 70.93% of the shares, indicating a concentrated ownership structure[16] - The company has no preferred shareholders or changes in restricted shares during the reporting period[18] Investments and Future Plans - The company reported a significant increase in investment income, which rose by 250.54% to ¥982,169.09 from ¥280,184.64 year-on-year[11] - The company plans to continue expanding its business in the probiotics and micro-ecological preparations sectors, which have shown significant growth[11] - The company plans to adjust the investment scale and structure of the food sector R&D production base project, reallocating surplus funds of ¥62.58 million to supplement working capital[21] - The project is expected to reach a usable state by December 31, 2026[21] - The company plans to expand its market presence and invest in new technologies to drive future growth[29] Research and Development - Research and development expenses were reported at ¥7,884,151.19, slightly down from ¥8,008,843.89 in the previous period[27] Audit Information - The first quarter report was not audited[32]

Financial Performance - The company's revenue for 2024 reached ¥302,793,277.36, representing a 1.19% increase compared to ¥299,241,834.45 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥94,356,080.46, a 0.94% increase from ¥93,479,909.00 in 2023[17]. - The cash flow from operating activities increased by 32.49% to ¥142,114,578.87 in 2024, compared to ¥107,266,756.69 in 2023[17]. - The total assets at the end of 2024 were ¥1,915,597,694.39, reflecting a 5.83% increase from ¥1,810,100,800.90 at the end of 2023[17]. - The basic earnings per share for 2024 was ¥0.36, up 2.86% from ¥0.35 in 2023[17]. - In 2024, the company's total revenue reached ¥302,793,277.36, with a gross margin of 58.25%, an increase of 1.19% compared to 2023[69]. - Direct sales contributed ¥296,272,380.22 to the revenue, with a gross margin of 58.30%, up from 54.69% in 2023[69]. - The distribution model accounted for only 2.15% of total revenue in 2024, with sales of ¥6,520,897.14 and a gross margin of 56.15%[69]. - The company reported a significant increase in sales of animal and plant micro-ecological preparations, with sales volume up by 66.77% to 1,680.43 tons[90]. - The gross margin for edible probiotics was 65.92%, with a year-on-year increase of 19.80% in revenue[89]. Market and Industry Trends - The global probiotic market is projected to grow from $61.1 billion in 2021 to $91.1 billion by 2026, with a CAGR of 8.3%[29]. - The Asia-Pacific region accounts for approximately 44.4% of global probiotic consumption, significantly higher than Europe (23.5%) and North America (17.8%)[29]. - The domestic probiotic market in China was valued at approximately 879.8 billion yuan in 2020, with an annual growth rate of 11-12% expected[29]. - By 2027, the domestic probiotic market size is expected to reach 149.6 billion yuan, with local manufacturers accounting for 74.8 billion yuan[32]. - The demand for probiotic products is anticipated to maintain rapid growth in the coming years, driven by increasing health awareness among consumers[33]. - The domestic postbiotics market is in its early stages but is expected to experience explosive growth, becoming a significant segment within the probiotic industry[33]. Research and Development - The company has been focusing on the research and development of probiotic products, which falls under the food manufacturing industry[26]. - The company possesses a resource library of over 50,000 strains of lactic acid bacteria, enabling targeted development of functional foods and dietary supplements[53]. - The company has invested significantly in R&D, conducting numerous clinical trials in collaboration with top hospitals to validate the beneficial functions of its core strains[74]. - Research and development expenses for 2024 amounted to CNY 36.33 million, reflecting a 6.24% increase compared to the previous year[83]. - The company is developing a unique gut microbiome database for the Chinese population, which is expected to support the application research of probiotics and enhance product development[99]. Product Development and Innovation - The company has introduced innovative probiotic products targeting weight management and oral health, enhancing its competitive edge in the market[83]. - The dual-protein probiotic fermented milk product is being developed to improve competitiveness and increase sales, with a focus on high probiotic counts and superior flavor profiles[99]. - The company aims to develop a new product line of probiotic tea beverages that meet consumer health demands, with high sensory ratings and probiotic counts[99]. - The company is actively developing products in collaboration with downstream beverage and baking enterprises to meet market demands, which may lead to rapid growth in the compound food additive business[51]. Strategic Partnerships and Collaborations - The company has established long-term stable strategic partnerships with leading enterprises in the dairy and pharmaceutical industries, enhancing customer cooperation and product development[76]. - The company has maintained close strategic partnerships with major dairy producers, enhancing cooperation in product development and research[50]. - The company is focusing on the core industries of lactic acid bacteria and probiotics, while compound food additives will continue to play a supplementary role in overall business growth[51]. Governance and Compliance - The company has established strict confidentiality protocols to protect core technologies and product formulas from leaks[144]. - The company has established performance evaluation standards and incentive mechanisms, ensuring transparency and compliance with legal regulations[157]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[158]. - The company has a clear governance structure that aligns with regulatory requirements, ensuring no significant discrepancies[160]. Employee Management and Development - The total number of employees at the end of the reporting period is 295, with 26 in the parent company and 269 in major subsidiaries[199]. - The company emphasizes a compensation system based on job roles and performance, ensuring market competitiveness and internal fairness[200]. - Employee benefits include mandatory social insurance and housing fund contributions, along with various welfare policies tailored to employee needs[200]. - The company is committed to the interaction between human capital appreciation and corporate capital growth, aligning employee value with corporate development[200]. Future Outlook and Expansion Plans - The company plans to expand its market presence and enhance its product offerings in the food and feed additive sectors[26]. - The company aims to achieve a comprehensive solution and a full range of products by 2025, focusing on the steady growth of probiotics and the development of compound food additives as a key supplement to its main business[132]. - The company plans to expand its business operations following the establishment of new subsidiaries[117]. - The company is exploring new strategies for market expansion and product development in response to consumer demand[123].

第一创业证券承销保荐有限责任公司 关于北京科拓恒通生物技术股份有限公司 2024 年度内部控制自我评价报告的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机 构"）作为北京科拓恒通生物技术股份有限公司（以下简称"科拓生物"或"公 司"）2022 年向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务 管理办法》《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定以及《企业 内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称 "企业内部控制规范体系"），对科拓生物《2024 年度内部控制自我评价报告》 进行了审慎核查，具体情况如下： 一、保荐机构进行的核查工作 一创投行保荐代表人通过与公司管理层及财务管理部、内部审计部等部门 的沟通交流，取得公司 2024 年度内部控制自我评价报告等相关信息资料；查阅 股东大会、董事会等会议记录、内部审计报告，以及各项业务和管理规则制度； 查阅公司董事会出具的 2024 年度内部控制自我评价报告，对公司内部控制的完 整、合理性及有效性进行了全面、认真的核查。 ...